PDS Biotechnology Corp (PDSB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PDS Biotechnology Corp (PDSB) has a cash flow conversion efficiency ratio of -0.400x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.70 Million) by net assets ($9.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
PDS Biotechnology Corp - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how PDS Biotechnology Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does PDS Biotechnology Corp carry for a breakdown of total debt and financial obligations.
PDS Biotechnology Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PDS Biotechnology Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Falcon Machine Tools Co Ltd
TWO:4513
|
-0.035x |
|
biote Corp
NASDAQ:BTMD
|
-0.150x |
|
Wisekey International Holding AG
NASDAQ:WKEY
|
-0.128x |
|
Nahar Industrial Enterprises Limited
NSE:NAHARINDUS
|
0.143x |
|
ImmuCell Corporation
NASDAQ:ICCC
|
-0.040x |
|
ZEN Graphene Solutions Ltd
NASDAQ:ZTEK
|
-0.103x |
|
Shinih Enterprise Co Ltd
TW:9944
|
0.008x |
|
Tunas Alfin Tbk
JK:TALF
|
0.034x |
Annual Cash Flow Conversion Efficiency for PDS Biotechnology Corp (2012–2025)
The table below shows the annual cash flow conversion efficiency of PDS Biotechnology Corp from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see PDS Biotechnology Corp stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $9.25 Million | $-27.75 Billion | -2999.623x | -162637.71% |
| 2024-12-31 | $19.00 Million | $-35.03 Million | -1.843x | -43.19% |
| 2023-12-31 | $26.13 Million | $-33.64 Million | -1.287x | -120.31% |
| 2022-12-31 | $44.00 Million | $-25.71 Million | -0.584x | -195.79% |
| 2021-12-31 | $63.21 Million | $-12.49 Million | -0.198x | +59.24% |
| 2020-12-31 | $27.13 Million | $-13.15 Million | -0.485x | +68.63% |
| 2019-12-31 | $11.70 Million | $-18.07 Million | -1.545x | -39.06% |
| 2018-12-31 | $29.84 Million | $-33.15 Million | -1.111x | -70.28% |
| 2017-12-31 | $62.37 Million | $-40.70 Million | -0.652x | -80.97% |
| 2016-12-31 | $89.28 Million | $-32.19 Million | -0.361x | -103.01% |
| 2015-12-31 | $122.48 Million | $-21.75 Million | -0.178x | -150.89% |
| 2014-12-31 | $-27.83 Million | $-9.71 Million | 0.349x | -33.40% |
| 2013-12-31 | $-15.35 Million | $-8.04 Million | 0.524x | -21.03% |
| 2012-12-31 | $-3.38 Million | $-2.25 Million | 0.664x | -- |
About PDS Biotechnology Corp
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies. The company's lead product candidate is Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, includin… Read more